

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M. 7559 - PFIZER / HOSPIRA**

**SECTION 1.2**

**Description of the concentration**

On 15 June 2015, the European Commission received a notification concerning a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004, by which Pfizer Inc. ("**Pfizer**"), a corporation incorporated under the laws of the State of Delaware, U.S.A., proposes to acquire sole control of Hospira, Inc. ("**Hospira**"), a corporation incorporated under the laws of the State of Delaware, U.S.A. within the meaning of Article 3(1)(b) of the Council of Regulation.

Pfizer is a global research based biomedical and pharmaceutical company active in discovering, developing, manufacturing, marketing, and selling innovative medicines for humans.

Hospira is a global provider of injectable drugs and infusion technologies, with a broad portfolio of generic, branded and biosimilar medicines for humans.